...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of investigative medicine >Impact of sustained virological response to chronic hepatitic C antiviral therapy on new onset diabetes mellitus type 2 after controlling for metabolic syndrome
【24h】

Impact of sustained virological response to chronic hepatitic C antiviral therapy on new onset diabetes mellitus type 2 after controlling for metabolic syndrome

机译：在控制代谢综合征后，在新发起糖尿病Mellitus 2型慢性丙型肝炎抗病毒治疗对慢性丙型肝炎抗病毒治疗的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The high cost associated with antiviral treatment for chronic hepatitis C virus (HCV) infection mandates further investigation in the context of preventing complications such as type 2 diabetes mellitus (DM2). We determined the cumulative incidence of DM2 in subjects with chronic HCV infection who received concomitant pegylated interferon (Peg-IFN) and ribavirin. We conducted a retrospective analysis of data obtained from Veterans Administrations Informatics and Computing Infrastructure (VINCI) to identify an adult cohort of patients without diabetes with chronic HCV infection who received Peg-IFN-based therapy between October 2001 and December 2011. Patients with history of HIV, hepatitis B infection, hepatocellular cancer (HCC), non-HCC cancers, and history of transplantation were excluded. Sustained virological response (SVR) was defined as negative HCV RNA 3 months after completion of therapy. Using Cox proportional hazards regression for multivariable analysis, we determined that patients who achieved SVR were at a significantly less risk of developing DM2. Adjusted survival rates showed that the responders' group was significantly less likely to develop DM2 over time (HR 0.60, CI 0.48 to 0.74, p0.001). Peg-IFN-based therapy in chronic HCV patients that resulted in SVR significantly decreased the risk of developing DM2 and independently predicts the development of new onset disease after controlling for correlates of metabolic syndrome.
机译：与慢性丙型肝炎病毒（HCV）感染抗病毒治疗相关的高成本要求在预防2型糖尿病（DM2）等中的并发症中进行进一步调查。我们确定了慢性HCV感染的受试者DM2的累积发病率，所述慢性HCV感染接受伴随的聚乙二醇化干扰素（PEG-IFN）和利巴韦林。我们对从退伍军人主管机关信息和计算基础设施（vinci）获得的数据进行了回顾性分析，以鉴定没有糖尿病的患者的成人队列，慢性HCV感染于2001年10月和2011年12月期间接受了基于PEG-IFN的治疗。历史患者艾滋病毒，乙型肝炎感染，肝细胞癌（HCC），非HCC癌症和移植史被排除在外。持续的病毒学反应（SVR）定义为治疗完成后3个月的阴性HCV RNA。使用Cox比例危害对多变量分析的回归，我们确定达到SVR的患者以显着较低的发展DM2风险。调整后的存活率表明，随着时间的推移，响应者组显着不太可能开发DM2（HR 0.60，CI 0.48至0.74，P <0.001）。基于PEG-IFN的治疗慢性HCV患者，导致SVR的患者显着降低了发展DM2的风险，并独立预测控制代谢综合征相关性后新发病疾病的发展。

著录项

  • 来源
    《Journal of investigative medicine》 |2017年第4期|共7页
  • 作者

    Pandya Prashant; Pant Chaitanya; Taylor Ryan; Oni Olurinde;

  • 作者单位

    Kansas City Vet Affairs Med Ctr 4801 E Linwood Blvd Kansas City MO 64128 USA;

    Kansas Univ Med Ctr Div Gastroenterol Hepatol &

    Motil Dept Internal Med Kansas City KS USA;

    Kansas Univ Med Ctr Div Gastroenterol Hepatol &

    Motil Dept Internal Med Kansas City KS USA;

    Kansas City Vet Affairs Med Ctr 4801 E Linwood Blvd Kansas City MO 64128 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 诊断学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号